Aimi Vaccine is the second largest and the largest private full-industry-chain vaccine group in China. The performance in 2023 shows that three blockbuster iterative upgraded vaccines are ready to be declared for listing. In 2023, a total of 14 clinical approval documents were obtained, and 21 clinical trials were carried out, of which 5 are in the final stage of Phase III clinical trials, and the production workshops of these 5 Phase III clinical vaccine products have been basically completed.

Up to now, Aimi Vaccine has several signature products: the Phase III clinical full-course immunization of the 13-valent pneumococcal conjugate vaccine (PCV13) under research has been completed, and the pre-review materials for listing application have been submitted to the National Medical Products Administration; the Phase III clinical trials of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and the serum-free iterative operation rabies vaccine have completed the full-course vaccination of the subjects, and are about to enter the unblinding stage. The globally pioneering innovative EV71-CA16 bivalent hand, foot and mouth disease vaccine (human diploid cells) has obtained clinical approval; the mRNA iterative rabies vaccine is the first non-COVID-19 mRNA vaccine product accepted in China.

Aimi Vaccine has currently commercialized eight vaccine products, among which, the recombinant hepatitis B vaccine and the Vero cell freeze-dried human rabies vaccine are in a leading position in the market. At present, the hepatitis B vaccine vaccination has been fully transferred from newborns to the whole population, and the company's sales revenue is expected to welcome a new increment.

The iterative upgraded rabies vaccine series, the company will successively launch serum-free iterative operation rabies vaccine, new technology high-efficiency human diploid rabies vaccine, and mRNA iterative operation rabies vaccine products, leading the deep technological iteration and upgrade of global rabies vaccines, and further consolidate the company's competitive advantage in the rabies vaccine market.

The iterative upgraded pneumonia vaccine series, the 13-valent pneumococcal conjugate vaccine has been submitted for pre-application for listing, and it is expected to apply for registration and listing within this year; the 23-valent pneumococcal polysaccharide vaccine is also expected to apply for registration and listing within this year; the 20-valent pneumococcal conjugate vaccine has submitted a pre-application for clinical trials; the globally synchronized first research 24-valent pneumococcal conjugate vaccine has completed preclinical research work. Just for the 13-valent pneumococcal conjugate vaccine, CIC Consultancy expects the market size in China will exceed 20 billion yuan in 2030.

In recent years, Aimi Vaccine has been maintaining high investment to promote the research and development of blockbuster upgraded large single products. In 2023, Aimi Vaccine's R&D expenses were 636 million yuan, a year-on-year increase of 27.2%, and the proportion of R&D revenue was 53.6%. From 2020 to 2023, the company's R&D expenditures were 158 million yuan, 307 million yuan, 500 million yuan, and 636 million yuan, with a compound annual growth rate of 59.1%.

In recent years, China's vaccine industry has strengthened its monopoly advantage in disease prevention, enhanced the status of Chinese vaccines in the overall biomedicine industry, and significantly increased the export of domestic vaccines. And Aimi Vaccine has also opened the door to the international market.

According to the annual report, Aimi Vaccine has recently started the registration work of the listed products in Southeast Asia, Africa, South America, the Middle East and other regions. Rabies vaccine has been registered and licensed in Pakistan and other countries. The R&D of new products keeps pace with international demand. Aimi Vaccine revealed that it is actively researching respiratory syncytial virus and herpes zoster vaccines, and striving to promote the listing registration and sales of products at home and abroad, and achieve the WHO pre-certification of vaccines. It can be seen that in the future, Aimi Vaccine will concentrate its resources, seize the types in short supply in the international market, which will bring huge growth space for the group's future development and revenue, and the future can be expected.